China’s Fosun Cleared for U.S. Trial of COVID-19 Antibody

China’s Fosun Pharmaceutical has received the FDA’s approval for a U.S. clinical trial of its investigational COVID-19 antibody treatment, HLX70.

Fosun subsidiary Hengenix Biotech will lead the early-stage study, which will evaluate the monoclonal antibody’s safety and pharmacokinetics in health volunteers.

The FDA has not yet authorized or approved any antibody treatments for COVID-19. But Eli Lilly and Regeneron Pharmaceuticals this week applied to the agency for Emergency Use Authorizations for their antibody products.